Survival factor NFIL3 restricts FOXO-induced gene expression in cancer

Genes and Development

Volumn 27, Issue 8, 2013, Pages 916-927

  Keniry, Megan ^a   Pires, Maira M ^a,b   Mense, Sarah ^b   Lefebvre, Celine ^a   Gan, Boyi ^c   Justiano, Karen ^a   Ingar Lau, Ying Ka ^a   Hopkins, Ben ^a   Hodakoski, Cindy ^a,b   Koujak, Susan ^a   Toole, Joseph ^a   Fenton, Franklyn ^a   Calahan, Ashley ^a   Califano, Andrea ^a   Depinho, Ronald A ^d   Maurer, Matt ^a,e   Parsons, Ramon ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

Apoptosis; Chromatin; FOXO; NFIL3; PTEN

Indexed keywords

BINDING PROTEIN; DNA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE DEACETYLASE 2; HYDROGEN PEROXIDE; NUCLEAR FACTOR INTERLEUKIN 3; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; CHROMATIN; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING;

APOPTOSIS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONE DEACETYLASES; HUMANS; KAPLAN-MEIER ESTIMATE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84876894862     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.214049.113     Document Type: Article

References (31)

1. Calnan DR, Brunet A. 2008. The FoxO code. Oncogene 27: 2276-2288.
2. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. 2011. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71.
3. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, et al. 2005. Robustness, scalability, and integration of a woundresponse gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci 102: 3738-3743.
4. Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, et al. 2010. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS ONE 5: e12293.
5. Cowell IG. 2002. E4BP4/NFIL3, a PAR-related bZIP factor with many roles. Bioessays 24: 1023-1029.
6. Fan W, Morinaga H, Kim JJ, Bae E, Spann NJ, Heinz S, Glass CK, Olefsky JM. 2010. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J 29: 4223-4236.
7. Gascoyne DM, Long E, Veiga-Fernandes H, de Boer J, Williams O, Seddon B, Coles M, Kioussis D, Brady HJ. 2009. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 10: 1118-1124.
8. Gialitakis M, Kretsovali A, Spilianakis C, Kravariti L, Mages J, Hoffmann R, Hatzopoulos AK, Papamatheakis J. 2006. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by trichostatin A. Nucleic Acids Res 34: 765-772.
9. Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A, Massagué J. 2006. A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci 103: 12747-12752.
10. Hong TM, Yang PC, Peck K, Chen JJ, Yang SC, Chen YC, Wu CW. 2000. Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol 23: 355-363.
11. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. 1997. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3 mediated survival of pro-B lymphocytes. Proc Natl Acad Sci 94: 2609-2614.
12. Kashiwada M, Levy DM, McKeag L, Murray K, Schroder AJ, Canfield SM, Traver G, Rothman PB. 2010. IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching. Proc Natl Acad Sci 107: 821-826.
13. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
14. Macgillavry HD, Cornelis J, van der Kallen LR, Sassen MM, Verhaagen J, Smit AB, van Kesteren RE. 2011. Genome-wide gene expression and promoter binding analysis identifies NFIL3 as a repressor of C/EBP target genes in neuronal outgrowth. Mol Cell Neurosci 46: 460-468.
15. Manning BD, Cantley LC. 2007. AKT/PKB signaling: Navigating downstream. Cell 129: 1261-1274.
16. Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y. 2001. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 61: 3741-3749.
17. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
18. Modur V, Nagarajan R, Evers BM, Milbrandt J. 2002. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937.
19. Ochiai K, Maienschein-Cline M, Mandal M, Triggs JR, Bertolino E, Sciammas R, Dinner AR, Clark MR, Singh H. 2012. A selfreinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat Immunol 13: 300-307.
20. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, et al. 2007. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323.
21. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. 2002. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2: 81-91.
22. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. 2007. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180.
23. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, et al. 2005. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
24. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
25. Simpson L, Li J, Liaw D, Hennessy I, Oliner J, Christians F, Parsons R. 2001. PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol Cell Biol 21: 3947-3958.
26. Stolarov J, Chang K, Reiner A, Rodgers L, Hannon GJ, Wigler MH, Mittal V. 2001. Design of a retroviral-mediated ecdysone- inducible system and its application to the expression profiling of the PTEN tumor suppressor. Proc Natl Acad Sci 98: 13043-13048.
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550.
28. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, et al. 2011. AKT/ FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146: 697-708.
29. Terragni J, Graham JR, Adams KW, Schaffer ME, Tullai JW, Cooper GM. 2008. Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and noncanonical activation of NFkB transcription factors. BMC Cell Biol 9: 6.
30. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
31. Zhang X, Yalcin S, Lee DF, Yeh TY, Lee SM, Su J, Mungamuri SK, Rimmele P, Kennedy M, Sellers R, et al. 2011. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol 13: 1092-1099.